drugset / Trial / NCT06206902
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Phase 1
Unknown
55 enrolled
Shanghai Simnova Biotechnology Co.,Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-01
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F01 | Cell therapy | 5e+08 cells | — |
| Subject | F01 | Cell therapy | 3e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |